India’s pharmaceutical packaging industry is projected to reach $3.65 billion by 2034, propelled by rising demand for safer, eco-friendly solutions amid expanding healthcare needs and regulatory changes.
India’s pharmaceutical packaging market is set for steady expansion as drug makers respond to rising demand for safer, more sustainable and more tightly regulated packaging, according to IMARC Group. The research firm estimates the market was worth $2.02 billion in 2025 and expects it to climb to $3.65 billion by 2034, reflecting a compound annual growth rate of 5.86%. West and Central India remained the largest regional market, helped by the concentration of manufacturing plants, research facilities and logistics networks.
The report says growth is being fuelled by several long-running trends in Indian healthcare. These include higher volumes of injectable drugs, biologics and vaccines, all of which require sterile formats such as vials and ampoules, as well as a wider burden of chronic illness that is increasing demand for prescription and over-the-counter medicines. IMARC also points to government support for domestic drug production through the Production Linked Incentive scheme and to rising exports, which together are expanding packaging demand across the industry.
Packaging design is also being reshaped by safety and compliance requirements. The report highlights growing use of child-resistant and tamper-evident features, alongside anti-counterfeit tools such as QR codes and track-and-trace systems. At the same time, sustainability is moving up the agenda, with companies under pressure to adopt recyclable, biodegradable or bio-based materials. IMARC notes that Indian policy initiatives, including the Council of Scientific and Industrial Research’s National Mission on Sustainable Packaging, are encouraging that shift.
By material, plastic remained the leading segment in 2025 because of its low cost, light weight and moisture resistance. By product, vials and ampoules led demand, reflecting the strength of injectable therapies. Pharma manufacturing was the largest end-user segment, while West and Central India held the biggest regional share. The competitive field includes ACG World, Amcor, AptarGroup, EPL, Huhtamaki India, PGP Glass, SCHOTT Poonawalla, SGD Pharma, UFlex and West Pharmaceutical Services. Recent developments cited by IMARC include Amcor’s expansion in Karnataka, TPG’s planned investment in SCHOTT Poonawalla and JPFL Films’ launch of BOPA nylon films for healthcare packaging.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
